Clinical Trials Logo

Filter by:
NCT ID: NCT04905290 Completed - Heart Failure Clinical Trials

Conduction System Pacing Optimized Therapy

CSPOT
Start date: November 27, 2021
Phase: N/A
Study type: Interventional

The purpose of the CSPOT study is to determine the best mode of cardiac resynchronization therapy (CRT) pacing for different populations of CRT patients, comparing traditional biventricular (BiV), conduction system pacing (CSP)-only, and conduction system pacing optimized therapy (CSPOT) also known as a combination of conduction system pacing (CSP) and left ventricular (LV) pacing. Additionally, safety of the system will be assessed.

NCT ID: NCT04903977 Completed - Clinical trials for Obstetric Complication

Detection of Obstetric Anal Sphincter Injuries With ONIRY Device

Start date: May 20, 2021
Phase: N/A
Study type: Interventional

The main purpose of the study is to confirm the clinical performance and safety of impedance spectroscopy using the ONIRY device for the detection of anal sphincter injuries arising from vaginal deliveries. The study group comprises 150 primiparous or multiparous women up to 8 weeks after the vaginal (spontaneous or assisted) delivery of singleton, live foetus, in any presentation, in gestational week 34 or more. The timeline for each subject in the study will be up to 5 weeks and will include 3 visits (V1-V3). All participants will be divided into 3 groups: A, B, C. Group A - subjects with no perineal tear signs, Group B - subjects with grade 1 or 2 per OASIS classification, and Group C - subjects with grade 3 or 4). The diagnostic performance will be evaluated in comparison to 3-D EUS (endoanal ultrasound) as a primary performance measure (primary endpoint).

NCT ID: NCT04893811 Completed - Clinical trials for Meningococcal Vaccine

Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age

Start date: August 18, 2021
Phase: Phase 4
Study type: Interventional

The aim of this study is to evaluate the safety, tolerability, and immunogenicity of 2 doses of Trumenba® (on a 0- and 6-month schedule) in immunocompromised participants by functionally assessing antibody production in asplenic and complement-deficient individuals ≥10 years of age.

NCT ID: NCT04889612 Completed - Stroke Clinical Trials

Motor Coordination and Grip Strength of the Dominant and Non-dominant Hand and Wrist in Post-stroke Patients.

Start date: August 5, 2019
Phase: N/A
Study type: Interventional

This study aimed to assess how stabilization of the trunk and the upper extremity can change the parameters of hand/wrist motor coordination and grip strength in dominant and non-dominant paretic upper limb, in post-stroke patients and neurologically healthy subjects.

NCT ID: NCT04887506 Completed - Clinical trials for Metastatic Castration-resistant Prostate Cancer

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

Start date: May 5, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the safety and efficacy of a new formulation of an existing drug product called TAVT-45 in patients with metastatic prostate cancer.

NCT ID: NCT04886544 Completed - Jaw Volume Deficit Clinical Trials

Clinical Study to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected for Jawline Contouring

Start date: June 25, 2021
Phase: N/A
Study type: Interventional

A Multicenter, Evaluator-Blinded, No-Treatment Control Design Clinical Study to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected for Jawline Contouring

NCT ID: NCT04886466 Completed - Stroke Clinical Trials

Importance of Core Stability for Coordinated Movement of the Human Body in Stroke Rehabilitation

Start date: August 10, 2019
Phase: N/A
Study type: Interventional

This is an observational study. Measurements were made during two different motor tasks: trunk tilts without and with the tension of the abdominal muscles in the sitting position and walking in a place with high knee lifting. It was checked how the intervention (active tension of the muscles stabilizing the core) changes the parameters of the motor coordination of the trunk and lower limbs.

NCT ID: NCT04884503 Completed - Clinical trials for Burning Mouth Syndrome

Evaluation of the Effectiveness of the Selected Method of Treatment of Primary Burning Mouth Syndrome

Start date: January 12, 2019
Phase: Phase 2
Study type: Interventional

The burning mouth syndrome (BMS) is a chronic pain syndrome of the oral mucosa. Feels like experiencing a burning sensation, pain, stinging, or numbness in the mouth along with a feeling of dryness, paraesthesia, taste disturbance or hypersensitivity.The complaints are usually bilateral, of moderate intensity, they persist for a minimum of 4-6 months and concern the clinically unchanged membrane mucous.The psychiatric aspect of BMS is very important. The presence of BMS has been shown to be associated with depression, increased anxiety levels, hypochondria, and carcinophobia and emotional instability

NCT ID: NCT04881461 Completed - Allergy Clinical Trials

A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis

Rhapsody
Start date: May 10, 2021
Phase: Phase 3
Study type: Interventional

This is a 2 year clinical study to compare 5-grass mix SLIT-drops with placebo in relieving grass pollen-induced rhinoconjunctivitis symptoms and in use of symptom-relieving medication during the second grass pollen season (peak grass pollen season, PGPS) The study will collect health-related quality of life data in the groups treated with 5-grass mix SLIT-drops or with placebo during the first and second PGPS. The trial medication used is already approved to treat allergic rhinitis caused by grass pollen in adults in several countries.

NCT ID: NCT04878354 Completed - Allergy Clinical Trials

A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis

TreeTop
Start date: April 7, 2021
Phase: Phase 3
Study type: Interventional

This is a clinical study in children and adolescents (5-17 years) with allergy to pollen from birch (or related trees). It compares the tree SLIT-tablet with placebo in relieving rhinoconjunctivitis symptoms during the birch/tree pollen season based on the average allergic rhinoconjunctivitis daily total combined score. The study will also collect health-related quality of life information in the groups treated with the tree SLIT-tablet or with placebo during the pollen season. The trial medication used is already approved to treat allergic rhinitis caused by birch/tree pollen in adults in several countries?.